Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Tasneem Lokhandwala, Nancy Smith, Catarina Sternhufvud, Elisabeth Sörstadius, Won Chan Lee & Jayanti Mukherjee. (2016) A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. Journal of Medical Economics 19:3, pages 203-212.
Read now
Read now
N. Sree Harsha. (2015) In Vitro and In Vivo Evaluation of Nanoparticles Prepared by Nano Spray Drying for Stomach Mucoadhesive Drug Delivery. Drying Technology 33:10, pages 1199-1209.
Read now
Read now
Matthew L. Mintz & Gianmaria Minervini. (2014) Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current Medical Research and Opinion 30:5, pages 761-770.
Read now
Read now
Giuseppe Derosa & Pamela Maffioli. (2012) Optimizing glycemic control: clinical utility of exenatide prolonged release injection. Research and Reports in Endocrine Disorders 2, pages 41-51.
Read now
Read now
André J Scheen. (2012) Saxagliptin plus metformin combination therapy. Expert Review of Endocrinology & Metabolism 7:2, pages 151-164.
Read now
Read now
André J Scheen. (2012)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 383-394.
Read now
Read now
André J Scheen. (2012) Metformin + saxagliptin for type 2 diabetes. Expert Opinion on Pharmacotherapy 13:1, pages 139-146.
Read now
Read now
Articles from other publishers (15)
Sanjay Kalra, Sarita Bajaj, AG Unnikrishnan, ManashP Baruah, Rakesh Sahay, V Hardik & Amit Kumar. (2019) Therapeutic experience of saxagliptin as first add-on after metformin in Indian type 2 diabetes patients: A non-interventional, prospective, observational study (ONTARGET-INDIA). Indian Journal of Endocrinology and Metabolism 23:3, pages 312.
Crossref
Crossref
Li-Guo Wang, Hui Wang, Qin Liu, Wei-Chang Hua & Chang-Ming Li. (2017) A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Biomedicine & Pharmacotherapy 92, pages 707-719.
Crossref
Crossref
Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung & Sang Jin Lee. (2017) Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. Journal of Diabetes 9:4, pages 412-422.
Crossref
Crossref
Giuseppe Derosa, Davide Romano, Lucio Bianchi, Angela D'Angelo & Pamela Maffioli. (2015) Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. The Journal of Clinical Pharmacology 55:4, pages 409-414.
Crossref
Crossref
R. E. Pratley, P. Fleck & C. Wilson. (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism 16:7, pages 613-621.
Crossref
Crossref
Giuseppe Derosa, Pietro Dario Ragonesi, Elena Fogari, Arrigo Francesco Giuseppe Cicero, Lucio Bianchi, Aldo Bonaventura, Davide Romano & Pamela Maffioli. (2014) Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundamental & Clinical Pharmacology 28:2, pages 221-229.
Crossref
Crossref
Joel M. Neutel, Cathy Zhao & Chetan S. Karyekar. (2013) Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. Diabetes Therapy 4:2, pages 269-283.
Crossref
Crossref
Giuseppe Derosa, Pietro D. Ragonesi, Anna Carbone, Elena Fogari, Angela D’Angelo, Arrigo F.G. Cicero & Pamela Maffioli. (2013) RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacological Research 73, pages 20-26.
Crossref
Crossref
Giuseppe DerosaArrigo F.G. CiceroIvano G. FranzettiFabrizio QuerciAnna CarboneMario N. PiccinniAngela D'AngeloElena FogariPamela Maffioli. (2013) A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study. Diabetes Technology & Therapeutics 15:3, pages 214-222.
Crossref
Crossref
Molly G. MinzeMary S. KleinBrian T. Terrell. (2013) Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S8510.
Crossref
Crossref
G. Derosa, I. G. Franzetti, F. Querci, A. Carbone, L. Ciccarelli, M. N. Piccinni, E. Fogari & P. Maffioli. (2012) Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Diabetic Medicine 29:12, pages 1515-1523.
Crossref
Crossref
Giuseppe Derosa, Anna Carbone, Ivano Franzetti, Fabrizio Querci, Elena Fogari, Lucio Bianchi, Aldo Bonaventura, Davide Romano, Arrigo F.G. Cicero & Pamela Maffioli. (2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Research and Clinical Practice 98:1, pages 51-60.
Crossref
Crossref
Giuseppe DerosaPietro D. RagonesiAnna CarboneElena FogariLucio BianchiAldo BonaventuraDavide RomanoArrigo F.G. CiceroPamela Maffioli. (2012) Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients. Diabetes Technology & Therapeutics 14:6, pages 475-484.
Crossref
Crossref
Giuseppe Derosa & Pamela Maffioli. (2012) Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review. Clinical Therapeutics 34:6, pages 1221-1236.
Crossref
Crossref
Giuseppe DerosaPamela Maffioli. (2012) Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience. Diabetes Technology & Therapeutics 14:4, pages 350-364.
Crossref
Crossref